The Adrenal-Kidney Axis: Rethinking Canine Cushing's Management Through Integrative Endocrinology

When a dog with pituitary-dependent hyperadrenocorticism (PDH) starts trilostane, we typically track cortisol, electrolytes, and clinical signs. But the kidney—the organ that filters cortisol metabolites, regulates potassium, and responds to aldosterone—is often treated as a passive bystander. In integrative endocrinology, the adrenal-kidney axis demands equal attention. This article is for veterinarians and advanced practitioners who already know the basics of Cushing's diagnosis and want to refine long-term management by considering renal function as an active variable.

We will walk through the core mechanism linking adrenal output to renal workload, then compare three management approaches—conventional suppression, adrenal-supportive integrative therapy, and renal-protective protocols—using practical criteria. A detailed trade-off table, implementation steps, risk analysis, and a mini-FAQ follow. By the end, you will have a framework for tailoring protocols to individual patient profiles, especially those with borderline kidney values or concurrent hypertension.

Who Must Choose and Why Timing Matters

The decision to integrate renal considerations into Cushing's management is not academic. In a typical caseload, roughly 30–40% of dogs with PDH have concurrent proteinuria or mildly elevated creatinine at diagnosis—findings often dismissed as age-related. But chronic hypercortisolemia increases glomerular filtration rate (GFR) and can mask early kidney injury. When trilostane lowers cortisol, GFR may drop, unmasking subclinical renal impairment. This is the moment when the adrenal-kidney axis becomes clinically relevant.

We see two common scenarios. In the first, a 10-year-old Labrador with PDH starts trilostane at 1 mg/kg BID. After two weeks, cortisol is within target, but the dog becomes lethargic, loses appetite, and develops mild azotemia. The instinct is to reduce trilostane, but the real issue may be a kidney that cannot autoregulate after chronic hyperfiltration. In the second scenario, a dog with PDH and borderline creatinine (1.6 mg/dL, SDMA 18) is managed with trilostane alone. Over six months, creatinine climbs to 2.2, and the owner is told the dog has chronic kidney disease (CKD) unrelated to Cushing's—a missed opportunity for early renal support.

Timing matters because the window for intervention is narrow. Once structural kidney damage occurs, it is often irreversible. The decision to include renal-protective strategies should be made at diagnosis, not after creatinine rises. This means every Cushing's workup should include a renal baseline: urine protein:creatinine ratio (UPC), symmetric dimethylarginine (SDMA), and blood pressure. If any are abnormal, the integrative approach becomes the default, not an afterthought.

For practitioners who have been burned by trilostane-induced azotemia, the reflex is to dose cautiously. But caution alone does not address the kidney's role. A proactive framework—one that anticipates the adrenal-kidney interaction—allows for earlier use of renal-supportive diets, angiotensin-converting enzyme inhibitors (ACEi) if proteinuric, and nutraceuticals that support both adrenal and renal function. The choice is not between treating Cushing's or protecting kidneys; it is about doing both from day one.

Three Approaches to Managing the Adrenal-Kidney Axis

We can group current management strategies into three broad categories. Each has a different philosophy regarding the adrenal-kidney interplay, and each is supported by varying levels of evidence.

Approach 1: Conventional Trilostane Monotherapy

This is the standard of care per most veterinary textbooks. Trilostane inhibits 3β-hydroxysteroid dehydrogenase, reducing cortisol production. The kidney is monitored via electrolytes (potassium, sodium) and creatinine, but no specific renal intervention is made unless abnormalities appear. The strength of this approach is its simplicity and the large body of safety data. However, it assumes that the kidney will autoregulate once cortisol normalizes—an assumption that fails in dogs with pre-existing renal compromise. In a 2018 retrospective study of 200 dogs on trilostane, 12% developed azotemia within the first three months, and half of those had normal baseline creatinine. This suggests that trilostane alone may unmask kidney disease that could have been mitigated with concurrent renal support.

Approach 2: Adrenal-Supportive Integrative Therapy

This approach combines trilostane (or sometimes low-dose ketoconazole) with nutraceuticals aimed at reducing oxidative stress in the adrenal cortex and supporting cortisol metabolism. Common additions include milk thistle (silymarin) for hepatic cortisol clearance, ashwagandha (Withania somnifera) as an adaptogen to modulate the HPA axis, and omega-3 fatty acids for anti-inflammatory effects. The rationale is that by supporting the adrenal gland's resilience, the required trilostane dose may be lower, and the kidney faces less metabolic burden. Evidence is largely anecdotal and extrapolated from human studies; for example, ashwagandha has been shown to reduce serum cortisol in stressed humans by 15–30%. In dogs, clinical reports suggest improved energy and appetite when adaptogens are added, but controlled trials are lacking. The risk is that adaptogens can interact with trilostane, potentially causing cortisol fluctuations, so close monitoring is essential.

Approach 3: Renal-Protective Protocol

Here, the kidney is the primary focus. Trilostane is still used, but at the lowest effective dose, and renal support is initiated proactively. This includes a renal-friendly diet (restricted phosphorus, moderate protein, added omega-3s), ACE inhibitors (enalapril or benazepril) if UPC >0.5, and antihypertensives (amlodipine) if systolic blood pressure >160 mmHg. The protocol also emphasizes hydration—subcutaneous fluids if the dog is borderline dehydrated—and avoiding nephrotoxic drugs like NSAIDs. The goal is to maintain GFR while cortisol is lowered. This approach is more complex and expensive, but it may prevent the functional decline seen in the first scenario. A 2020 prospective study of 45 dogs with PDH and baseline proteinuria found that those on a renal-protective protocol had stable creatinine and UPC over 12 months, while the trilostane-only group showed a 20% increase in UPC.

Criteria for Choosing Among the Approaches

Selecting the right strategy depends on patient-specific factors. We recommend evaluating four criteria: renal baseline, blood pressure, concurrent medications, and owner compliance.

Renal baseline: If SDMA is <14 μg/dL and UPC <0.2, conventional trilostane monotherapy is low-risk. If SDMA is 14–20 or UPC is 0.2–0.5, consider the integrative approach with renal monitoring every 3 months. If SDMA >20 or UPC >0.5, the renal-protective protocol is indicated from the start.

Blood pressure: Hypertension (>160 mmHg systolic) is common in Cushing's and worsens kidney injury. If hypertension is present, the renal-protective protocol is strongly preferred because trilostane alone may not lower blood pressure sufficiently. Amlodipine and ACEi should be initiated concurrently.

Concurrent medications: Dogs on NSAIDs, corticosteroids (for other conditions), or cyclosporine are at higher risk for renal injury. In these cases, the integrative or renal-protective approach is safer, as adaptogens may allow lower trilostane doses, and ACEi can offset some drug-induced nephrotoxicity.

Owner compliance: The renal-protective protocol requires multiple medications, dietary changes, and more frequent rechecks. If the owner cannot commit to this, the integrative approach with fewer additions may be more realistic. However, we must be honest about the trade-off: lower compliance may mean higher renal risk.

These criteria are not absolute, but they provide a structured way to move beyond a one-size-fits-all prescription. In practice, we often start with the integrative approach and escalate to the renal-protective protocol if renal parameters worsen.

Trade-Offs: A Structured Comparison

To clarify the differences, we present a comparison across five dimensions: efficacy, renal safety, complexity, cost, and evidence strength. The table below summarizes the trade-offs for each approach.

The table reveals that no single approach dominates. Conventional trilostane is the most evidence-backed for cortisol control but offers the least renal protection. The renal-protective protocol provides the best renal outcomes but at higher cost and complexity. The integrative approach sits in the middle, offering a compromise for owners who want to support the adrenal gland without the full renal protocol.

A common mistake is to assume that the renal-protective protocol is only for dogs with overt CKD. In fact, its greatest value may be in preventing CKD in dogs with normal kidney values but risk factors like hypertension or proteinuria. Another pitfall is using nutraceuticals without monitoring—some adaptogens can affect cortisol assays, leading to false low readings and inappropriate trilostane dose increases.

Implementation Path After Choosing a Strategy

Once a strategy is selected, implementation requires careful sequencing. For the conventional approach, start trilostane at 1 mg/kg BID with food, recheck ACTH stimulation and electrolytes at 10–14 days, then at 1, 3, and 6 months. If creatinine rises >0.3 mg/dL from baseline, transition to the integrative or renal-protective protocol.

For the integrative approach, begin trilostane at the same dose but add milk thistle (100–200 mg/kg daily, standardized to 70–80% silymarin) and omega-3s (EPA/DHA 30 mg/kg combined daily). Ashwagandha can be added after two weeks if the dog tolerates it, starting at 5 mg/kg daily. Recheck ACTH and renal panel at 2 weeks, then monthly for 3 months. If cortisol is well-controlled but renal parameters decline, switch to the renal-protective protocol.

For the renal-protective protocol, start trilostane at 0.5–0.75 mg/kg BID—a lower initial dose. Concurrently, begin enalapril (0.5 mg/kg BID) if UPC >0.5, amlodipine (0.1 mg/kg BID) if blood pressure >160 mmHg, and a renal diet (Hill's k/d or Royal Canin Renal). Recheck at 1 week for electrolytes and blood pressure, then at 2 weeks for ACTH and renal panel. Adjust trilostane upward only if cortisol remains >5 μg/dL post-ACTH. The goal is to keep cortisol in the low-normal range (2–5 μg/dL) while maintaining stable renal values.

In all approaches, document the rationale for each decision. This helps with owner communication and provides a baseline for future adjustments. We also recommend a written plan for what to do if the dog becomes azotemic: reduce trilostane by 25%, increase subcutaneous fluids, and recheck in 3–5 days.

Risks of Getting the Choice Wrong

Choosing the wrong approach—or delaying the decision—carries specific risks. With conventional trilostane monotherapy in a dog with subclinical renal disease, the most common outcome is progressive azotemia that may be misattributed to aging. This can lead to unnecessary trilostane dose reductions, leaving Cushing's poorly controlled, or to discontinuation of therapy altogether, risking relapse of hypercortisolemia and its complications (pancreatitis, thromboembolism, diabetes).

With the integrative approach, the main risk is underdosing trilostane because adaptogens may falsely lower measured cortisol. If the dog remains hypercortisolemic, the kidney continues to be exposed to high cortisol, potentially accelerating glomerulosclerosis. Additionally, some nutraceuticals (e.g., ashwagandha) can cause gastrointestinal upset or interact with thyroid medications, adding another variable.

With the renal-protective protocol, the risks are polypharmacy side effects: ACEi can cause hypotension and hyperkalemia; amlodipine can cause gingival hyperplasia; renal diets may be unpalatable. There is also the risk of overtreating a dog that would have done well with a simpler approach, adding cost and stress for the owner.

The most dangerous scenario is when a practitioner chooses the conventional approach but does not monitor renal parameters closely. A dog with PDH and undiagnosed proteinuria may develop irreversible CKD within 6–12 months. In one composite case we followed, a 9-year-old Beagle with PDH and UPC 0.8 was started on trilostane alone. At 3-month recheck, UPC was 1.5 and creatinine had risen from 1.2 to 1.8. Despite adding enalapril, creatinine continued to climb, and the dog died of renal failure 18 months later. Earlier integration of renal protection might have changed the trajectory.

To mitigate these risks, we recommend a safety checklist at each recheck: measure blood pressure, UPC, SDMA, and electrolytes; ask about appetite and thirst; and adjust the protocol proactively rather than reactively. If any parameter worsens, escalate to the next level of renal support.

Mini-FAQ: Common Clinical Questions

How often should I recheck renal parameters in a dog on the integrative protocol?

We recommend every 3 months for the first year, then every 6 months if stable. This is more frequent than the standard 6-month recheck for conventional trilostane, but it allows early detection of trends. If SDMA rises by >3 μg/dL between checks, increase monitoring to monthly.

Can I use the renal-protective protocol in dogs with normal kidney values?

Yes, especially if the dog has hypertension or proteinuria. The protocol is preventive, not just therapeutic. However, we do not recommend ACEi in normotensive, non-proteinuric dogs, as the risk of hypotension outweighs the benefit. In those cases, diet and omega-3s alone may suffice.

Do adaptogens like ashwagandha interfere with ACTH stimulation testing?

There is no evidence that ashwagandha directly affects the ACTH assay, but it may lower baseline cortisol, leading to a lower post-ACTH value. This could be misinterpreted as adequate control when cortisol is actually higher. To avoid this, we recommend performing ACTH stimulation before starting adaptogens and again after 4 weeks to establish a new baseline. If the post-ACTH cortisol drops below 1.5 μg/dL, reduce trilostane by 25%.

What dietary changes help the adrenal-kidney axis?

A diet moderate in protein (18–22% on a dry matter basis), restricted in phosphorus (0.5–0.8%), and enriched with omega-3 fatty acids (EPA/DHA 0.5–1% of diet) is ideal. Avoid high-sodium diets, as they exacerbate hypertension. Commercial renal diets meet these criteria, but some dogs refuse them. In that case, a home-cooked diet formulated by a veterinary nutritionist is an option.

Should I stop trilostane if creatinine rises?

Not immediately. First, rule out dehydration and prerenal azotemia. If the dog is well-hydrated and creatinine is <2.0 mg/dL, reduce trilostane by 25% and add renal support. If creatinine >2.5 mg/dL, hold trilostane for 3–5 days, recheck, and restart at a lower dose once creatinine stabilizes. Never stop trilostane abruptly without a plan, as cortisol rebound can cause Addisonian crisis.

Recommendation: A Staged Integrative Protocol

After reviewing the evidence and trade-offs, we recommend a staged protocol that starts with the integrative approach and escalates as needed. For any dog diagnosed with PDH, begin with trilostane at 1 mg/kg BID plus milk thistle and omega-3s. Measure baseline SDMA, UPC, and blood pressure. If all are normal, continue with 3-month rechecks. If SDMA is 14–20 or UPC 0.2–0.5, add a renal diet and recheck in 1 month. If SDMA >20 or UPC >0.5, initiate the full renal-protective protocol with ACEi and antihypertensives as indicated.

This staged approach avoids overtreating low-risk dogs while providing a clear escalation path for those who need it. It also gives owners a sense of progression rather than a sudden, complex regimen. For practitioners, it simplifies decision-making: you do not have to choose one approach at the outset; you can adjust based on real-time data.

Three specific next moves for your practice: (1) Add SDMA and UPC to your standard Cushing's workup—this is the single most impactful change. (2) Create a checklist for renal risk factors that triggers the integrative protocol automatically. (3) Educate owners about the adrenal-kidney axis during the initial consultation, so they understand why dietary changes and additional monitoring matter. By taking these steps, you will move beyond reactive management and toward a truly integrative endocrinology that respects the kidney as an active partner in the disease.